Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 May;54(5):1811-4.
doi: 10.1128/AAC.01716-09. Epub 2010 Mar 15.

Effect of ceftaroline on normal human intestinal microflora

Georgios Panagiotidis  1 , Tobias Bäckström, Charlotte Asker-Hagelberg, Alena Jandourek, Andrej Weintraub, Carl Erik Nord
Affiliations
Clinical Trial

Effect of ceftaroline on normal human intestinal microflora

Georgios Panagiotidis et al. Antimicrob Agents Chemother. 2010 May.

Abstract

Ceftaroline is a new broad-spectrum cephalosporin being developed for the treatment of serious bacterial infections, including those caused by aerobic Gram-positive and Gram-negative bacteria. The purpose of the present study was to investigate the effect of administration of ceftaroline on the intestinal flora of healthy subjects. Twelve healthy subjects (6 males and 6 females), 20 to 41 years of age, received ceftaroline (600 mg) by intravenous infusion every 12 h (q12h) for 7 days. Plasma and feces were collected for determination of ceftaroline concentration and analysis of fecal flora. Fecal specimens were cultured on nonselective and selective media. Different colony types were counted, isolated in pure culture, and identified to the genus level. All new strains of colonizing bacteria were tested for susceptibility to ceftaroline. The concentrations of ceftaroline in plasma were as follows: on day 2, 17.5 to 34.8 mg/liter; on day 5, 19.7 to 33.2 mg/liter; and on day 7, 18.0 to 29.8 mg/liter. No ceftaroline concentrations were found on day -1, 9, 14, or 21. No measurable concentrations in feces were found on day -1, 2, 5, 7, 9, 14, or 21. There was a minor impact on the numbers of Escherichia coli strains, while the numbers of enterococci and Candida albicans strains were not affected. There were moderate decreases in the numbers of bifidobacteria and lactobacilli during the first 7 days, while the numbers of clostridia increased during the same period. No impact on the numbers of Bacteroides bacteria was noticed. No new colonizing aerobic or anaerobic bacteria resistant to ceftaroline (MIC >or= 4 mg/liter) were found. Ceftaroline had no significant ecological impact on the human intestinal microflora.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Effect of ceftaroline administration on the aerobic intestinal microflora of 12 subjects. The solid line represents the median values for logarithmic number of microorganisms/g feces.
FIG. 2.
FIG. 2.
Effect of ceftaroline administration on the anaerobic intestinal microflora of 12 subjects. The solid line represents the median values for logarithmic number of microorganisms/g feces.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. CLSI. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
    1. CLSI. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 7th ed. Approved standard M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA. - PubMed
    1. Ge, Y., D. Biek, G. H. Talbot, and D. F. Sahm. 2008. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:3398-3407. - PMC - PubMed
    1. Huang, H., A. Weintraub, H. Fang, and C. E. Nord. 2009. Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of Clostridium difficile infections. J. Clin. Microbiol. 47:3729-3731. - PMC - PubMed
    1. Murray, P. R., E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.). 2007. Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.

Publication types